It is our pleasure to welcome you to the 2nd ELRIG bi-annual conference on Advances in Cell Based Screening in Drug Discovery to be held on the 10th and 11th of May 2017 at AstraZeneca in Gothenburg. This interactive 2-day event will host leading scientists from academia and industry, coming together to discuss the latest developments in cell based screening in drug discovery.
Cell based assays and screens are utilized in drug discovery to explore disease mechanisms and identify novel molecular therapeutics. Significant efforts have therefore been dedicated to developing cell-based assay platforms capable of providing a more accurate biological context and thus reduce the number of animal tests, improve translation to human physiology/pathophysiology and accelerate the drug discovery process.
Recent developments in assay and detection technologies have improved the sensitivity in drug screening and, together with the application of native cell systems, including primary and stem cell derived cellular models, in early hit and lead identification means that potential novel therapeutic molecules are being applied to human cellular systems earlier than ever.
The program for this ELRIG meeting has been developed to expand scientific horizons in key topic areas such as advanced cell models, applied omics, assays/methods exploring mode of action, phenotypic screening, target deconvolution, and much more. Speakers from leading laboratories, both academic and industrial, will present and discuss the latest updates and advances in cellular systems and drug discovery platforms. Throughout the course of the two day conference, you will get an exclusive opportunity to network and be involved in inspiring and interesting discussions with scientists and researchers from the pharmaceutical, academic and vendor communities.
There will be opportunities for scientists to network and discuss challenges and solutions relating to current and breakthrough assay technologies and provide a platform to assess the true value and impact of new and innovative approaches to cell based drug discovery.
Day 1: 10th May 2017
Advanced Cellular Models
Modern cell-based screening is underpinned by a range of increasingly advanced cellular models to mimic native human biology in a dish. This session will focus on an exciting range of approaches to enable native-like cell experimentation. The scene will be set by one of the leaders in the organoid space, an original member of the team who discovered how to expand, in vitro, the then newly discovered gut stem cell niche and who has continued to exploit the findings to generate complex human multicellular models that are being applied in several basic and applied research initiatives. The session presentations will go on to show application of novel approaches including stem cell based derivation of pancreatic cells, use of human primary cells to predict toxicity and model hepatic disease and, finally, characterisation of extracellular matrix components influencing lung regeneration through tissue-derived multi-potent progenitor cells in a bioreactor setting. Taken together, this will provide conference attendees with a sense of the breadth and depth of options available to researchers aiming to model human biology and disease and will be useful as platform to compare the strengths of the various approaches.
‘Omics for Screening and Profiling
Multiple omics technologies (genomics, transcriptomics, metabolomics, proteomics) are applied with the aim of generating data from humans as well as model organisms to gain insight into disease aetiology and to understand the underlying pathophysiological mechanisms and to stratify potential therapeutic strategies. These rapidly developing technologies are intrinsically accompanied by simultaneous development of computational tools necessary for analysis and interpretation of such data which are set to revolutionize modern medical science. In this session, two leading scientists in next-generation omics-technologies will provide examples of how these technologies can be applied to explore novel biology and/or pharmacology. They will share their recent work on single-cell expression analysis to identify cell types and lineages of the mouse nervous system and applying proteogenomic studies to identify functionally coupled drug target proteins for rational selection for combination treatment in oncology. The session will provide the attendees with an insight into two rapidly developing technologies in the “omics” area and their applications.
Day 2: 11th May 2017
Target Engagement & Deconvolution and Applied Phenotypic Screening
The application and focus on phenotypic screening as a drug discovery paradigm has increased dramatically over the last several years due to advancements in phenotypic readouts in improved and more relevant in vitro disease models, recapitulating clinically relevant biology. In these sessions, clinically inspired phenotypic screening are described together with the advancements relating to novel approaches in MoA determinations and target deconvolution to demonstrate the synergies in these approaches to drive a step change in drug discovery. The theme of the session will be introduced by a keynote from a leader in the phenotypic discovery space who will share and discuss strategies, challenges and the state of the art technologies underpinning phenotypic discovery approaches. The session presentations will go on to discuss novel approaches to MoA determinations and target deconvolution, including methods such as chemoproteomics, protein thermal profiling, cellular thermal shift assays (CETSA) and other applications including methods applied for biologics. The session will end with case study presentations with examples from the metabolism, neuro sciences and oncology therapeutic areas, applying these methods to unravel the underlying biology. Taken together, this will provide the attendees with an overview of the advancements in the phenotypic discovery area and approaches to overcome challenges in target deconvolution and/or MoA determinations.
Advanced Cellular Models
‘Omics for Screening and Profiling
Target Engagement & Deconvolution
Applied Phenotypic Screening
University of Edinburgh Cancer Research Centre
For Poster Presenters
Poster presentations at Advances in Cell Based Screening 2017 are an excellent opportunity for delegates to network with colleagues and communicate their research FREE OF CHARGE. To be considered for a poster presentation, you must first submit an abstract for review by the meeting’s Scientific Program Committee.
For those wishing to participate, a subset of abstracts will also be considered for a short, poster taster session involving a 10 minute oral presentation within the main Symposia sessions. Decisions regarding acceptance of poster abstracts and/or selection for Poster Tasters will be communicated via e-mail at the end of February.
Deadlines for Submission:
24th March 2017: Poster Taster Spot
5th May 2017: General Poster Submission
All presenters must be registered as full-conference attendees in order to present at Advances in Cell Based Screening 2017.
Poster size should be no larger than A0 Portrait (W: 841mm x H: 1189mm).
ELRIG organizers will provide supplies to mount your posters, including Velcro and/or pushpins.
We apologise that we are unable to accommodate posters which are any larger than A0 Portrait.
Posters from Exhibiting Companies:
As an exhibitor, you have one poster spot included with your stand package.
Additional poster spots are £250 +VAT each.
Posters from Non-Exhibiting Companies:
Non-exhibiting vendor companies will be charged £250 +VAT for each poster submitted.
The speaker’s reception will take place on Tuesday 9th May 2017 with drinks at 7.30 and buffet from 8pm. The reception will take place at the AstraZeneca site:
Pepparedsleden 1, Mölndal